Astellas Pharma ALPMY Stock
Astellas Pharma Price Chart
Astellas Pharma ALPMY Financial and Trading Overview
| Astellas Pharma stock price | 16.85 USD |
| Previous Close | 16.51 USD |
| Open | 16.76 USD |
| Bid | 16.82 USD x 211300 |
| Ask | 16.86 USD x 200000 |
| Day's Range | 16.75 - 17.38 USD |
| 52 Week Range | 12.1 - 17.38 USD |
| Volume | 22.43K USD |
| Avg. Volume | 106.59K USD |
| Market Cap | 30.21B USD |
| Beta (5Y Monthly) | 0.076 |
| PE Ratio (TTM) | 12.389706 |
| EPS (TTM) | 1.36 USD |
| Forward Dividend & Yield | 0.5 (2.93%) |
| Ex-Dividend Date | March 31, 2026 |
| 1y Target Est | 17.4 USD |
ALPMY Valuation Measures
| Enterprise Value | 218.6B USD |
| Trailing P/E | 12.389706 |
| Forward P/E | 37.444447 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.012695051 |
| Price/Book (mrq) | 2.4112713 |
| Enterprise Value/Revenue | 0.092 |
| Enterprise Value/EBITDA | 0.288 |
Trading Information
Astellas Pharma Stock Price History
| Beta (5Y Monthly) | 0.076 |
| 52-Week Change | 38.79% |
| S&P500 52-Week Change | 13.32% |
| 52 Week High | 17.38 USD |
| 52 Week Low | 12.1 USD |
| 50-Day Moving Average | 15.25 USD |
| 200-Day Moving Average | 14.82 USD |
ALPMY Share Statistics
| Avg. Volume (3 month) | 106.59K USD |
| Avg. Daily Volume (10-Days) | 138.39K USD |
| Shares Outstanding | 1.79B |
| Float | 1.79B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.025% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 79 |
| Trailing Annual Dividend Yield | 478.49% |
| 5 Year Average Dividend Yield | 344.00% |
| Payout Ratio | 0.17549999 |
| Last Split Factor | 125:100 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2026 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | March 31, 2027 |
Profitability
| Profit Margin | 16.20% |
| Operating Margin (ttm) | 23.54% |
| Gross Margin | 80.84% |
| EBITDA Margin | 31.89% |
Management Effectiveness
| Return on Assets (ttm) | 10.03% |
| Return on Equity (ttm) | 21.44% |
Income Statement
| Revenue (ttm) | 2.38T USD |
| Revenue Per Share (ttm) | 1328.16 USD |
| Quarterly Revenue Growth (yoy) | 20.10% |
| Gross Profit (ttm) | 1.92T USD |
| EBITDA | 759.08B USD |
| Net Income Avi to Common (ttm) | 385.58B USD |
| Diluted EPS (ttm) | 1.36 |
| Quarterly Earnings Growth (yoy) | 26.10% |
Balance Sheet
| Total Cash (mrq) | 238.23B USD |
| Total Cash Per Share (mrq) | 132.86 USD |
| Total Debt (mrq) | 424.92B USD |
| Total Debt/Equity (mrq) | 21.42 USD |
| Current Ratio (mrq) | 1.313 |
| Book Value Per Share (mrq) | 6.988015 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 547.64B USD |
| Levered Free Cash Flow (ttm) | 348.19B USD |
Profile of Astellas Pharma
| Country | United States |
| State | N/A |
| City | Chuo |
| Address | 2-5-1, Nihonbashi-Honcho |
| ZIP | 103-8411 |
| Phone | 81 3 3244 3000 |
| Website | https://www.astellas.com |
| Industry | Drug Manufacturers - General |
| Sector(s) | Healthcare |
| Full Time Employees | 14099 |
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Q&A For Astellas Pharma Stock
What is a current ALPMY stock price?
Astellas Pharma ALPMY stock price today per share is 16.85 USD.
How to purchase Astellas Pharma stock?
You can buy ALPMY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Astellas Pharma?
The stock symbol or ticker of Astellas Pharma is ALPMY.
Which industry does the Astellas Pharma company belong to?
The Astellas Pharma industry is Drug Manufacturers - General.
How many shares does Astellas Pharma have in circulation?
The max supply of Astellas Pharma shares is 1.79B.
What is Astellas Pharma Price to Earnings Ratio (PE Ratio)?
Astellas Pharma PE Ratio is 12.38970600 now.
What was Astellas Pharma earnings per share over the trailing 12 months (TTM)?
Astellas Pharma EPS is 1.36 USD over the trailing 12 months.
Which sector does the Astellas Pharma company belong to?
The Astellas Pharma sector is Healthcare.
